[ad_1]
Original title: the third thousand yuan A share was born. Amico’s net profit of 440 million yuan has a market value of 100 billion yuan.
Affected by strong yield growth in 2020 and large-scale dividends, Amic’s share price on the 9th rose above 1,000 yuan, becoming the third 1,000-yuan share on the A-share market. day, Aimeike’s daily limit closed at 1,088.40 yuan, with a total market value of 130.8 billion yuan. After the market, Amic received a letter of concern from the Shenzhen Stock Exchange and was asked to provide further explanations on the rationale for the profit-sharing plan.
On the night of the 8th, Amic published its first annual report after listing. The annual report shows that the company’s annual revenue for 2020 is 709 million yuan, a year-on-year increase of 27.18%; Net profit attributable to shareholders of listed companies is 440 million yuan, an increase of 43.93%, earnings per share is 4.51 yuan. At the same time, the company stated that it intends to distribute a cash dividend of RMB 35 (tax included) for every 10 shares to all shareholders based on the total share capital of 120 million shares at the end of 2020, and a total cash dividend of 421 million RMB, 10 shares were converted into 8 shares.
Amic was listed in the growth business market on September 28, 2020. Its leading sodium hyaluronate-related injectable product, hyaluronic acid, has attracted market attention due to its high growth performance and high gross profit since its quotation. In terms of operating performance, affected by factors such as the epidemic, Amic will achieve a revenue growth rate of 27.18% and a net profit growth rate of 43.93% in 2020, which represents a drop compared to the previous three years. Public information shows that from 2017 to 2019, the company earned revenue of 222 million yuan, 321 million yuan and 558 million yuan, an increase of 58.09%, 44.28% and 73.74% year-on-year; Net earnings attributable to the parents were 82 million yuan, 123 million yuan and 306 million yuan, an increase of 53.99%, 49.47% and 148.68% year on year. Gross profit margin remains high Annual report shows Amico’s gross profit margin in 2020 is 92.59%.
It is understood that Amec’s main products mainly include Yimei, Bonida, Aphry, Hi-body, Yimei One Plus One and Aimefei. The revenue and gross profit margin of the company come primarily from the above hyaluronic acid products. From 2017 to 2019, sales revenue from the above products accounted for more than 99% of top business revenue. The latest annual report shows that in 2020, the company’s solution and gel injection products will continue to account for 98.63% of revenue.
This revenue structure means that the excessive concentration of Amico products in the hyaluronic acid field has not changed. Amic said in its annual report that the company has formed a combined design that includes differentiated injections of sodium hyaluronate, injections containing microspheres, botulinum toxin type A, implant thread and weight management products. However, in terms of revenue, the revenue from facial implants in 2020 is 1.8422 billion yuan, which is only 0.26% of revenue. In addition, botulinum toxin type A injectable for dynamic wrinkle removal and liraglutide injection for chronic weight management are in the clinical stage. The annual report shows that in Amec’s current research and development line, only the medical sodium hyaluronate gel project containing modified poly-L-lactic acid microspheres for skin filler has entered the registration stage. and application, which is still a hyaluronic acid product.
It is worth noting that on the same day, Aimeike received a letter of concern from the Shenzhen Stock Exchange due to a 35 yuan profit distribution plan for 10 to 8 distribution. The Shenzhen Stock Exchange requested the company that complements the main considerations, basis and rationale for the formulation of the profit distribution plan, whether it coincides with the growth of the performance of the company and the proponent, the company’s planning and the decision-making process of the profit distribution plan. In addition, the Shenzhen Stock Exchange noted that from January 4 to February 8, 2021, the company’s share price increased 38.47%, while the ChiNext stock index rose 0.08% during the same period, and asked Amic to add that the The company has accepted interviews with the media and institutional investigations in the last month. Circumstances, if there is a situation that violates the principle of impartiality in the disclosure of information, such as the leakage of undisclosed material information to specific investors, and if there is a situation that cooperates with speculation in share prices.
